Stojiljkovic M, Klaassen K, Djordjevic M, Sarajlija A, Brasil S, Kecman B, Grkovic S, Kostic J, Rodriguez-Pombo P, Desviat L R, Pavlovic S, Perez B
Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Belgrade, Serbia.
Mother and Child Health Care Institute of Serbia "Dr Vukan Cupic", School of Medicine, University of Belgrade, Belgrade, Serbia.
Clin Genet. 2016 Sep;90(3):252-7. doi: 10.1111/cge.12751. Epub 2016 Mar 4.
Specific mitochondrial enzymatic deficiencies in the catabolism of branched-chain amino acids cause methylmalonic aciduria (MMA), propionic acidemia (PA) and maple syrup urine disease (MSUD). Disease-causing mutations were identified in nine unrelated branched-chain organic acidurias (BCOA) patients. We detected eight previously described mutations: p.Asn219Tyr, p.Arg369His p.Val553Glyfs17 in MUT, p.Thr198Serfs6 in MMAA, p.Ile144_Leu181del in PCCB, p.Gly288Valfs11, p.Tyr438Asn in BCKDHA and p.Ala137Val in BCKDHB gene. Interestingly, we identified seven novel genetic variants: p.Leu549Pro, p.Glu564, p.Leu641Pro in MUT, p.Tyr206Cys in PCCB, p.His194Arg, p.Val298Met in BCKDHA and p.Glu286_Met290del in BCKDHB gene. In silico and/or eukaryotic expression studies confirmed pathogenic effect of all novel genetic variants. Aberrant enzymes p.Leu549Pro MUT, p.Leu641Pro MUT and p.Tyr206Cys PCCB did not show residual activity in activity assays. In addition, activity of MUT enzymes was not rescued in the presence of vitamin B12 precursor in vitro which was in accordance with non-responsiveness or partial responsiveness of patients to vitamin B12 therapy. Our study brings the first molecular genetic data and detailed phenotypic characteristics for MMA, PA and MSUD patients for Serbia and the whole South-Eastern European region. Therefore, our study contributes to the better understanding of molecular landscape of BCOA in Europe and to general knowledge on genotype-phenotype correlation for these rare diseases.
支链氨基酸分解代谢过程中特定的线粒体酶缺陷会导致甲基丙二酸尿症(MMA)、丙酸血症(PA)和枫糖尿症(MSUD)。在9名无亲缘关系的支链有机酸尿症(BCOA)患者中鉴定出致病突变。我们检测到8个先前描述的突变:MUT基因中的p.Asn219Tyr、p.Arg369His、p.Val553Glyfs17,MMAA基因中的p.Thr198Serfs6,PCCB基因中的p.Ile144_Leu181del,BCKDHA基因中的p.Gly288Valfs11、p.Tyr438Asn以及BCKDHB基因中的p.Ala137Val。有趣的是,我们鉴定出7个新的基因变异:MUT基因中的p.Leu549Pro、p.Glu564、p.Leu641Pro,PCCB基因中的p.Tyr206Cys,BCKDHA基因中的p.His194Arg、p.Val298Met以及BCKDHB基因中的p.Glu286_Met290del。计算机模拟和/或真核表达研究证实了所有新基因变异的致病作用。在活性测定中,异常酶p.Leu549Pro MUT、p.Leu641Pro MUT和p.Tyr206Cys PCCB未显示出残余活性。此外,在体外存在维生素B12前体的情况下,MUT酶的活性未得到恢复,这与患者对维生素B12治疗无反应或部分反应一致。我们的研究为塞尔维亚及整个东南欧地区的MMA、PA和MSUD患者带来了首批分子遗传学数据和详细的表型特征。因此,我们的研究有助于更好地了解欧洲BCOA的分子格局以及这些罕见疾病基因型-表型相关性的一般知识。